Conditions: Multiple Sclerosis
Keywords: ATX-MS-1467 (MSC2358825A) Relapsing Multiple Sclerosis Magnetic resonance imaging (MRI) M2736
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 37
Healthy volunteers: no

Brief summary:
This is a multi-center, open-label, single arm, baseline-controlled Phase 2a trial to evaluate the clinical and biological effects of ATX-MS-1467 in subjects with relapsing multiple sclerosis (MS) and to assess the maintenance of any such effects.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: ATX-MS-1467
Intervention descriptions: intervention 1: Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.

Protocol document: